Skip to content
The Policy VaultThe Policy Vault

Strensiq (asfotase alfa) — United Healthcare

juvenile-onset hypophosphatasia

Initial criteria

  • Diagnosis of perinatal/infantile-onset hypophosphatasia OR diagnosis of juvenile-onset hypophosphatasia

Reauthorization criteria

  • Documentation of positive clinical response to Strensiq therapy

Approval duration

12 months